Associated Papers
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype.
Sobieralski P et al.
Frontiers in Oncology, 2023
Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Wu QY et al.
International Journal of Biological Macromolecules, 2019
The New Genomics: What Molecular Databases Can Tell Us About Human Population Variation and Endocrine Disease.
Rotwein P
Endocrinology, 2017
Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.
Dalton WB et al.
Jco Precision Oncology, 2017
The reliable assurance of detecting somatic mutations in cancer-related genes by next-generation sequencing: the results of external quality assessment in China.
Zhang R et al.
Oncotarget, 2016
Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.
Silvennoinen O et al.
Blood, 2015
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
Shan Y et al.
Nature Structural & Molecular Biology, 2014
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN et al.
The Biochemical Journal, 2014
JAK2 inhibition for the treatment of hematologic and solid malignancies.
Harry BL et al.
Expert Opinion on Investigational Drugs, 2012
A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation.
Zhao L et al.
The Journal of Biological Chemistry, 2009
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH et al.
Cancer Genetics and Cytogenetics, 2009
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
Journal of Cellular and Molecular Medicine, 2009
Consistent up-regulation of Stat3 Independently of Jak2 mutations in a new murine model of essential thrombocythemia.
Senyuk V et al.
Cancer Research, 2009
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W et al.
Seminars in Cell & Developmental Biology, 2008
[The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi, 2008
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C et al.
Leukemia, 2008
The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA et al.
Human Pathology, 2008
JAK2 mutations other than V617F: a novel mutation and mini review.
Karow A et al.
Leukemia Research, 2008
Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
Inami M et al.
Leukemia, 2008
JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.
Vicente C et al.
Leukemia, 2007
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Schnittger S et al.
Leukemia, 2007
JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Steensma DP
The Journal of Molecular Diagnostics : Jmd, 2006
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP et al.
Leukemia, 2006
The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW et al.
Oncogene, 2006